Article

[Hepatitis B and C serologic markers in blood donors of the Ribeirão Preto Blood Center].

Hemocentro de Ribeirão Preto, Ribeirão Preto, SP, Brazil.
Revista da Sociedade Brasileira de Medicina Tropical (Impact Factor: 0.93). 12/2005; 38(6):488-92. DOI: 10.1590/S0037-86822005000600008
Source: PubMed

ABSTRACT The investigation involved 25,891 blood donors who attended for the first time the Blood Center of Ribeirão Preto, Brazil, between Jun 23, 1996 and Jun 22, 2001. The objective was to study the proportion of positive serological markers for hepatitis B and C at the initial screening tests and to estimate the prevalence of such infections through the analysis of confirmatory tests, carried out at the University Hospital as a part of the patients evaluation. Data from the donors and laboratory results were obtained from the records of both the Blood Bank and the Hospital. The population of donors was mainly composed by males (83.6%) and by individuals between 26 and 45 (64%) years of age. The proportions of positive results in screening tests were 0.6% (CI95%: 0.54-0.72) for HBsAg and 1.2% (CI95%: 1.02-1.28) for anti-HCV. Confirmatory testes showed values of prevalence of 0.2% (CI95%: 0.16-0.28) for hepatitis B and 0.3% (IC95%: 0.24-0.38) for hepatitis C.

0 Bookmarks
 · 
40 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) infection is a global health problem estimated to affect almost 200 million people worldwide. The aim of this study is to analyze the subtypes and existence of variants resistant to protease inhibitors and their association with potential HCV risk factors among blood donors in Brazil. Repeat anti-HCV reactive blood donors are systematically asked to return for retest, notification, and counseling in which they are interviewed for risk factors for transfusion-transmitted diseases. We analyzed 202 donors who returned for counseling from 2007 to 2010 and presented enzyme immunoassay- and immunoblot-reactive results. The HCV genotypes and resistance mutation analyses were determined by the direct sequencing of the NS5b and NS3 regions, respectively. The HCV viral load was determined using an in-house real-time PCR assay targeting the 5'-NCR. HCV subtypes 1b, 1a, and 3a were found in 45.5%, 32.0%, and 18.0% of the donors, respectively. The mean viral load of genotype 1 was significantly higher than that of the genotype 3 isolates. Subtype 1a was more frequent among young donors and 3a was more frequent among older donors. Protease inhibitor-resistant variants were detected in 12.8% of the sequenced samples belonging to genotype 1, and a higher frequency was observed among subtype 1a (20%) in comparison to 1b (8%). There was no difference in the prevalence of HCV risk factors among the genotypes or drug-resistant variants. We found a predominance of subtype 1b, with an increase in the frequency of subtype 1a, in young subjects. Mutations conferring resistance to NS3 inhibitors were frequent in treatment-naïve blood donors, particularly those infected with subtype 1a. These variants were detected in the major viral population of HCV quasispecies, have replicative capacities comparable to nonresistant strains, and could be important for predicting the response to antiviral triple therapy.
    PLoS ONE 01/2014; 9(1):e86413. · 3.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic infection with hepatitis C virus (HCV) is a major and growing public health concern worldwide, including in Latin America. With more efficacious therapies becoming available, decision-makers will require accurate estimates of disease prevalence to assess the potential impact of new treatments. However, few estimates of the epidemiologic burden, either overall or by country, are available for Latin America; and the potential impact of currently-available treatments on the epidemiologic burden of HCV in Latin America has not been assessed. To address this, we systematically reviewed twenty-five articles presenting population-based estimates of HCV prevalence from general population or blood donor samples, and supplemen- ted those with publically-available data, to estimate the total number of persons infected with HCV in Latin America at 7.8 million (2010). Of these, over 4.6 million would be expected to have genotype 1 chronic HCV, based on published data on the risk of progression to chronic disease and the HCV genotype distribution of Latin America. Finally, we calculated that between 1.6 and 2.3 million persons with genotype 1 chronic HCV would potentially benefit from current treatments, based on published estimates of genotype-specific treatment responsiveness. In conclusion, these estimates demonstrate the substantial present epidemiologic burden of HCV, and quantify the impending societal and clinical burden from untreated HCV in Latin America.
    Annals of hepatology: official journal of the Mexican Association of Hepatology 09/2012; 11(5):623-35. · 1.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: So that an improvement in the selection of donors can be achieved and the risk to the recipient of transfused blood can be reduced, prospective donors are submitted to clinical and serological screening. This study investigated the blood discard rate and the rate of infectious and contagious diseases in blood donors from provincial towns of the state of Paraná, Brazil. This study was an exploratory cross-sectional descriptive investigation with a quantitative approach of donations between January and December 2011. In the study period the Regional Blood center in Maringá, Brazil received 8337 blood donations from people living in the city and neighboring towns. However, 278 (3.33%) donations were discarded during serological screening owing to one or more positive serological markers. A total of 46.4% of the discarded blood units were confirmed positive by serology with anti-HBc being the most common (66.7%), followed by syphilis (22.5%), HBsAg (4.7%), anti-hepatitis C virus (3.1%), human immunodeficiency virus (1.5%) and Chagas' disease (1.5%). The rate of infectious-contagious diseases that can be transmitted by blood transfusions was 1.55% (129/8337) of the donor population with a frequency of 1.03% for anti-HBc and 0.35% for syphilis. This study demonstrates a high prevalence of the anti-HBc marker in prospective blood donors from provincial towns in the state of Paraná, Brazil.
    Revista Brasileira de Hematologia e Hemoterapia 01/2013; 35(6):395-9.

Full-text (3 Sources)

View
2 Downloads
Available from
May 19, 2014